Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Indigenous Women's Experiences With Perinatal Nursing Care: Beyond Deficit Narratives to Work Toward Sovereign Wellbeing.

ANS. Advances in nursing science·2026

Same author

Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trial.

The lancet. HIV·2026

Same author

Assessing current diagnostic, staging, and treatment practices in community and academic centers for individuals with stage IB-IIIA non-small cell lung cancer.

Translational lung cancer research·2026

Same author

HER-2 Altered Early-Stage Non-Small Cell Lung Cancer Had Better Survival than Triple-Negative Disease.

Journal of clinical medicine·2026

Same author

Nurses' Perspectives on Cancer Care for People Who Experience Incarceration in British Columbia, Canada: Challenges and Opportunities.

The Canadian journal of nursing research = Revue canadienne de recherche en sciences infirmieres·2026

Same journal

Clonal divergence with acquired BRAF V600E in NSCLC with compound EGFR G719X/S768I after prolonged EGFR-TKI therapy.

Lung cancer (Amsterdam, Netherlands)·2026

Same journal

Corrigendum to "European experience on oncological outcomes of patients with early stage non-small cell lung cancer and any prior cancer following lobectomy or segmentectomy" [Lung Cancer J. 217 (2026) 109410].

Lung cancer (Amsterdam, Netherlands)·2026

Same journal

Proportion of lung cancer patients eligible for screening in France: Data from the KBP-2020-CPHG study.

Lung cancer (Amsterdam, Netherlands)·2026

Same journal

Prevalence and characteristics of NTRK fusions in 25,946 patients with non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands)·2026

Same journal

Prognostic impact of the 9th vs 8th TNM classification in small-cell lung cancer. a population-based study.

Lung cancer (Amsterdam, Netherlands)·2026

Same journal

Corrigendum to "European experience on oncological outcomes of patients with early-stage non-small cell lung cancer and any prior cancer following lobectomy or segmentectomy" Published in [Lung Cancer https://doi.org/10.1016/j.lungcan.2026.109410].

Lung cancer (Amsterdam, Netherlands)·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 9, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

EGFR mutation testing across the osimertinib clinical program.

Marie Laure Murat-Onana¹, Suresh S Ramalingam², Pasi A Jänne³

¹Precision Medicine & Biosamples, AstraZeneca, Cambridge, UK.

Lung Cancer (Amsterdam, Netherlands)

|May 1, 2025

Summary

This summary is machine-generated.

Most tissue samples are adequate for EGFR testing in non-small cell lung cancer (NSCLC). Optimizing pre-analytic variables and tissue sampling is crucial for improving EGFR mutation test success rates.

Keywords:

EGFR mutation testing EGFR mutations Non-small cell lung cancer Osimertinib

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Experiment Videos

Last Updated: May 9, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Area of Science:

Oncology
Molecular Diagnostics
Cancer Biomarkers

Background:

Epidermal Growth Factor Receptor (EGFR) mutations are key drivers in non-small cell lung cancer (NSCLC).
EGFR-tyrosine kinase inhibitors (TKIs), such as osimertinib, have transformed NSCLC treatment.
Accurate and early identification of EGFR mutations is critical for effective patient management.

Purpose of the Study:

To analyze EGFR mutation tissue testing data from clinical trials of osimertinib in NSCLC.
To identify challenges and factors affecting the success of EGFR mutation testing.
To support best practices for EGFR mutation testing in NSCLC.

Main Methods:

Pooled analysis of central Cobas® EGFR Mutation Test data from nine global osimertinib NSCLC clinical trials.
Evaluation of specimen adequacy and test validity based on specimen type, disease stage, and geographical region.
Analysis of reasons for testing inadequacy, including insufficient tumor content and tissue volume.

Main Results:

Out of 4,864 biopsies and 2,402 resections, 91% were adequate for testing.
Biopsies showed 12% inadequacy (mainly insufficient tumor/tissue), while resections had 3% inadequacy.
Testing inadequacy varied by disease stage, being higher in advanced/metastatic settings and unresectable stage III.
Test success rates for adequate specimens ranged from 93% to 99%.

Conclusions:

The majority of tissue specimens are suitable for EGFR mutation testing.
Insufficient tissue or tumor content are primary reasons for testing inadequacy, particularly in biopsies and advanced disease stages.
Optimizing pre-analytic variables and tissue sampling techniques is essential to enhance EGFR testing success rates in NSCLC.